Trial Profile
Longitudinal Study of Long-term (36 Month) Cognitive Outcomes in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD) Who Have Previously Had PET Imaging With 18F-AV-45 Injection.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Oct 2014
Price :
$35
*
At a glance
- Drugs Florbetapir F 18 (Primary)
- Indications Alzheimer's disease; Mild cognitive impairment
- Focus Diagnostic use
- Sponsors Avid Radiopharmaceuticals
- 15 Oct 2014 New trial record